XSPRAY PHARMA AB (PUBL)

Xspray Pharma (Nasdaq Stockholm: XSPRAY) is a Swedish-based pharmaceutical company founded in 2003 with the goal of enhancing patients' quality of life through the development and production of pharmaceuticals. The company specializes in utilizing innovative, patented, and scalable technology to create improved versions of existing drugs, primarily focusing on protein kinase inhibitors (PKIs) for cancer treatment. With a strong pipeline of product candidates and the HyNap technology, Xspray Pharma aims to enter the market before secondary patents expire, ensuring rapid patient benefits. The company's first product, XS0004 dasatinib, is awaiting FDA approval and has obtained orphan drug status in the US. Xspray Pharma's management team brings extensive experience in the pharmaceutical industry. The company's shares are publicly traded on Nasdaq Stockholm, and their commitment to utilizing leading-edge technology and industry expertise places them at the forefront of the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries. In November 2024, Xspray Pharma secured a kr100.00M Post-IPO Debt investment from Buntel and Fenja Capital II, showcasing strong investor confidence in the company's future prospects. For more information, visit www.xspraypharma.com.